# Trabectedin Maintenance Post 1st-line in STS

> **NCT02929394** · PHASE3 · TERMINATED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 13 (actual)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** Trabectedin

## Key facts

- **NCT ID:** NCT02929394
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-07
- **Primary completion:** 2020-06-05
- **Final completion:** 2020-06-05
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2020-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02929394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02929394, "Trabectedin Maintenance Post 1st-line in STS". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02929394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*